Log in

NASDAQ:TLRYTilray Stock Price, Forecast & News

$6.96
-0.05 (-0.71 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.89
Now: $6.96
$7.28
50-Day Range
$6.96
MA: $8.88
$10.81
52-Week Range
$2.43
Now: $6.96
$48.48
Volume4.18 million shs
Average Volume9.59 million shs
Market Capitalization$869.03 million
P/E RatioN/A
Dividend YieldN/A
Beta3.25
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.
Read More
Tilray logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLRY
CUSIPN/A
CIKN/A
Phone206-432-9325

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$166.98 million
Book Value$2.78 per share

Profitability

Net Income$-321,170,000.00
Net Margins-241.79%

Miscellaneous

Employees1,646
Market Cap$869.03 million
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable

Receive TLRY News and Ratings via Email

Sign-up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter.

Tilray (NASDAQ:TLRY) Frequently Asked Questions

How has Tilray's stock been impacted by COVID-19 (Coronavirus)?

Tilray's stock was trading at $7.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TLRY stock has decreased by 1.8% and is now trading at $6.96. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tilray?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 2 sell ratings, 12 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tilray.

When is Tilray's next earnings date?

Tilray is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Tilray.

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) announced its quarterly earnings data on Monday, May, 11th. The company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($0.44) by $1.29. The business earned $52.20 million during the quarter, compared to analysts' expectations of $49.37 million. Tilray had a negative net margin of 241.79% and a negative return on equity of 62.82%. The firm's revenue was up 127.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.27) EPS. View Tilray's earnings history.

What price target have analysts set for TLRY?

16 analysts have issued 1 year price targets for Tilray's stock. Their forecasts range from $4.00 to $31.00. On average, they anticipate Tilray's stock price to reach $12.77 in the next year. This suggests a possible upside of 83.5% from the stock's current price. View analysts' price targets for Tilray.

Has Tilray been receiving favorable news coverage?

Media coverage about TLRY stock has trended negative recently, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tilray earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the near term. View the latest news about Tilray.

Who are some of Tilray's key competitors?

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Advanced Micro Devices (AMD), Aphria (APHA) and Square (SQ).

Who are Tilray's key executives?

Tilray's management team includes the following people:
  • Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
  • Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
  • Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
  • Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company acted as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

How do I buy shares of Tilray?

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $6.96.

How big of a company is Tilray?

Tilray has a market capitalization of $869.03 million and generates $166.98 million in revenue each year. The company earns $-321,170,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Tilray employs 1,646 workers across the globe.

What is Tilray's official website?

The official website for Tilray is www.tilray.com.

How can I contact Tilray?

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The company can be reached via phone at 206-432-9325.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.